FDA: For Niaspan Reduced Flushing Claim, Pre-Defined Criteria Necessary
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott would also need a “good-sized study” to support such a claim, CDER Metabolism and Endocrinology Products Deputy Director Colman tells “The Pink Sheet” DAILY.
You may also be interested in...
Merck’s Lipid-Lowering Combo Cordaptive Could Clear FDA In Mid-2008
The company announced it has filed the niacin and laropiprant combination, formerly known as MK-0524A.
Merck’s Lipid-Lowering Combo Cordaptive Could Clear FDA In Mid-2008
The company announced it has filed the niacin and laropiprant combination, formerly known as MK-0524A.
Merck Vaccine Unit Tops $1 Billion In Second Quarter Sales On Strength Of New Products
Gardasil sales, however, were down sequentially compared to the first quarter.